BenevolentAI progresses BEN-34712 for ALS treatment

BenevolentAI, a clinical-stage AI development company, has announced the successful delivery of its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS), BEN-34712.

Related Keywords

,Richard Mead ,Anne Phelan ,Sheffield Institute For Translational Neuroscience Sitra ,University Of Sheffield ,Sheffield Institute ,Translational Neuroscience ,Bio Developments ,Hi ,Artificial Intelligence ,Clinical Trials ,Drug Discovery ,